Personalized Genetic Testing for pain medication effectiveness provides an invaluable service to physicians and patients throughout the U.S.
Thousands of Tests Performed
Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.
20+ Years Experience
Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.
Fast 5-Day Turnaround
Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.
Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.
The PGT Analgesic Panel supports doctors in determining the appropriate pain medications and doses that are best suited for a patient’s genetic profile. Learn more about our genetic testing for pain medications below.
PGT Analgesic Panel provides genetic results for:
|CYP2B6||Responsible for the metabolism of the most active metabolite of methadone|
|CYP2C9||Responsible for the metabolism of most NSAID pain medications|
|CYP2C19||Has been connected to the metabolism of Carisoprodol, a skeletal muscle relaxant|
|CYP2D6||Has been revealed to have an important outcome on the body’s ability to metabolize the opioids Oxycodone, Codeine, and Tramadol|
|CYP3A4/A5||Affects the body’s ability to metabolize Fentanyl|
The test also offers genotypes for COMT and OPRM1. When patients have COMT and OPRM1 genetic testing, these two pharmacodynamic genes that have been associated with the therapeutic response of patients taking opioid medications. With OPRM1 gene testing, physicians can better determine treatment plans.
PGT Analgesic Panel can help define the appropriateness and dosage of many of these prescribed drugs including:
|Therapeutic Class||Name of Drug|
Tramadol Hydrochloride / Acetaminophen (Ultracet®)
|Muscle Relaxants||Carisoprodol (Soma®)